We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis' (NVS) Leukemia Drug Meets Goal in Late-Stage Study
Read MoreHide Full Article
Novartis AG (NVS - Free Report) announced positive data from a late-stage study, ASCEMBL, on pipeline candidate, asciminib, for the treatment of chronic myeloid leukemia.
Asciminib (ABL001) is an investigational treatment, specifically targeting the ABL myristoyl pocket (STAMP). ASCEMBL is a phase III, multicenter, open-label, randomized study comparing asciminib with Pfizer’s (PFE - Free Report) Bosulif in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine-kinase inhibitors (TKIs).
The study met its primary endpoint of statistically significant superiority in major molecular response (MMR) rate at 24 weeks for asciminib as compared to bosutinib.
The results of the study will be shared with regulatory authorities. We remind investors that the FDA has granted Fast Track designation to asciminib.
Per the company, by specifically targeting the ABL myristoyl pocket, STAMP inhibition has the potential to help address resistance and intolerance in later treatment lines for CML.
The successful development of the candidate will strengthen Novartis’ oncology portfolio as it looks to fortify the core pharma business after having undertaken a series of restructuring measures and divesting its non-core businesses. Novartis’ Tasigna is already approved for CML.
The stock has lost 8.1% in the year so far against the industry’s growth of 2%.
Last month, Novartis’ second-quarter results were hit by the coronavirus pandemic as sales fell short of expectations. Nevertheless, Cosentyx maintains momentum for the company on recent label expansions, despite stiff competition from AbbVie’s (ABBV - Free Report) Humira, and Taltz and Johnson & Johnson’s (JNJ - Free Report) Tremfya. However, the FDA recently approved a label update for ophthalmology drug, Beovu, to include additional safety information regarding retinal vasculitis and retinal vascular occlusion. The growth trajectory that Beovu takes up following this label update is yet to be seen.
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early. See the 5 high-tech stocks now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Novartis' (NVS) Leukemia Drug Meets Goal in Late-Stage Study
Novartis AG (NVS - Free Report) announced positive data from a late-stage study, ASCEMBL, on pipeline candidate, asciminib, for the treatment of chronic myeloid leukemia.
Asciminib (ABL001) is an investigational treatment, specifically targeting the ABL myristoyl pocket (STAMP). ASCEMBL is a phase III, multicenter, open-label, randomized study comparing asciminib with Pfizer’s (PFE - Free Report) Bosulif in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine-kinase inhibitors (TKIs).
The study met its primary endpoint of statistically significant superiority in major molecular response (MMR) rate at 24 weeks for asciminib as compared to bosutinib.
The results of the study will be shared with regulatory authorities. We remind investors that the FDA has granted Fast Track designation to asciminib.
Per the company, by specifically targeting the ABL myristoyl pocket, STAMP inhibition has the potential to help address resistance and intolerance in later treatment lines for CML.
The successful development of the candidate will strengthen Novartis’ oncology portfolio as it looks to fortify the core pharma business after having undertaken a series of restructuring measures and divesting its non-core businesses. Novartis’ Tasigna is already approved for CML.
The stock has lost 8.1% in the year so far against the industry’s growth of 2%.
Last month, Novartis’ second-quarter results were hit by the coronavirus pandemic as sales fell short of expectations. Nevertheless, Cosentyx maintains momentum for the company on recent label expansions, despite stiff competition from AbbVie’s (ABBV - Free Report) Humira, and Taltz and Johnson & Johnson’s (JNJ - Free Report) Tremfya. However, the FDA recently approved a label update for ophthalmology drug, Beovu, to include additional safety information regarding retinal vasculitis and retinal vascular occlusion. The growth trajectory that Beovu takes up following this label update is yet to be seen.
Novartis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>